S
The startup develops laboratory-based diagnostic tests utilizing artificial intelligence, algorithms, and epigenomic profiling to detect all major subtypes of breast cancer from stage 1 to 4. With a sensitivity and specificity of 98.5%, their tests enable early and accurate cancer diagnosis, improving treatment outcomes for patients.
Kingston, Jamaica
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops laboratory-based diagnostic tests utilizing artificial intelligence, algorithms, and epigenomic profiling to detect all major subtypes of breast cancer from stage 1 to 4. With a sensitivity and specificity of 98.5%, their tests enable early and accurate cancer diagnosis, improving treatment outcomes for patients.